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Abstract
Background: Assisted vaginal birth is a vital health intervention that can result in better outcomes for mothers and
their babies when complications arise in the second stage of labour. Unfortunately, instruments for assisted vaginal
birth (forceps and ventouse) are often not utilised in settings where there is most clinical need, resulting in maternal
and neonatal morbidity and mortality which could have been prevented. The BD Odon Device is a new device for
assisted vaginal birth that may be able to address this unmet need. However, before dissemination, the device requires
evaluation in robust clinical trials. A feasibility study to investigate the clinical impact, safety, and acceptability of the BD
Odon Device for assisted vaginal birth is therefore planned. This will provide further information on acceptability,
recruitment, and the outcome data required to design a future randomised controlled trial of the BD Odon Device
versus Kiwi ventouse.
Methods: Forty women who require an assisted vaginal birth for a recognised clinical indication will have the birth
assisted with the BD Odon Device. The primary outcome is successful vaginal birth completed with the BD Odon
Device. Secondary clinical outcomes include maternal and neonatal outcomes, and maternal and practitioner
satisfaction. Safety data will be reviewed following every birth.
Discussion: A future randomised controlled trial of the BD Odon Device versus the current standard instrument (the
Kiwi ventouse) is planned. The findings of the ASSIST Study will inform the randomised controlled trial design.
Trial registration: ISRCTN, ISRCTN10203171. Prospectively registered on 27 July 2018.
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Background
Complications of the second stage of labour (fetal com-
promise, obstructed labour, maternal exhaustion, or ma-
ternal medical conditions exacerbated by the act of
pushing) remain a major cause of maternal and neonatal
mortality and morbidity across the world. Such compli-
cations are responsible for 4% to 13% of maternal deaths
in Africa, Asia, Latin America, and the Caribbean [1],
and in 2013 obstructed labour alone accounted for four
deaths per million women worldwide [2]. This burden of
adverse outcomes may be reduced by an appropriately
timed and safely performed assisted vaginal birth (AVB).
An AVB is performed with either obstetric forceps or
ventouse, and reduces adverse outcomes for women and
their babies relative to caesarean section performed in
the second stage of labour [3]. However, AVB rates are
minimal in low- and middle-income countries (LMICs)
where it is likely that there is the greatest need for AVB
(Fig. 1).
In addition to widespread low levels of utilisation, earlier
surveys report significant regions where AVB was not used
at all—in 2006 this was the case in 74% of Latin American
and Caribbean countries, as well as 30% of countries in
sub-Saharan Africa and 40% of countries in Asia [4]. In
addition to a lack of trained accouchers in LMICs [5–7],
the maintenance and sterilisation requirements of both
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forceps and ventouse may limit their utilisation [4]. There
is a significant unmet need for AVB in all maternity set-
tings, but particularly in LMICs.
Forceps are less likely to fail in achieving an AVB when
compared to a ventouse; however, they are associated with
increased maternal perineal and vaginal trauma. The
ventouse is less likely to achieve a vaginal birth and its
use is associated with an increased risk of neonatal
cephalohaematoma and retinal haemorrhage [8]. Both
devices are efficient but do have caveats for their use. It
is possible that a new device may be able to address
some of the adverse events associated with the current
devices used to assist birth.
The BD Odon Device is a new device for AVB (Fig. 2).
The use of an air chamber to act as the traction point
on the fetal head (rather than the thin metal blades of
the forceps) is hypothecated to reduce adverse events
associated with the greater pressures applied to the fetal
head during the use of forceps. The lack of negative
pressure on the fetal head, the mechanism of action of
the ventouse, obviates the risk of haematoma and haem-
orrhage associated with ventouse. Both of these conten-
tions have been supported in pre-clinical simulation
studies [9, 10]. A first-in-human pilot study of an earlier
version of the device in healthy volunteers has been
completed and demonstrated that assisting birth using
the device is feasible [11]. Following the completion of
extensive simulation studies which included human
factor engineering validation testing, it has been deemed
appropriate to evaluate the BD Odon Device in the
intended target user population [12]. To date, the effect-
iveness and safety of the Odon device compared with
other devices remains untested. It is now time to evalu-
ate the clinical effectiveness and safety of the BD Odon
Device in its intended clinical setting, using an appropri-
ately powered and robust randomised controlled trial
(RCT). To inform the design of this study we plan to
conduct a safety and feasibility study exploring the
clinical impact that the BD Odon device may have on
current clinical practice, as well as the safety and accept-




This feasibility study will investigate the clinical impact,
safety, and acceptability of the BD Odon Device and
assess the feasibility of recruiting women and data col-
lection. It will provide vital information on acceptability,
recruitment, and the outcome data required to design a
future RCT of the BD Odon Device versus the Kiwi
ventouse.
Study design
The ASSIST Study (Assisted Vaginal Birth Study) is a
non-randomised feasibility study of 40 women who
require an assisted vaginal birth for a recognised clinical
indication and who will all have their birth assisted with
the BD Odon Device. A CONSORT diagram of the
feasibility study is shown in Fig. 3.
The ASSIST feasibility study will utilise only one of
the devices intended for use in the eventual randomised
controlled study (BD Odon Device). This is to establish
the safety, acceptability, and efficacy of the BD Odon
Fig. 1 Percentage of births as AVBs in selected countries, 2008 to 2015. Data adapted from [18–21]
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Device prior to moving to a full RCT. The intended
comparator (the Kiwi ventouse) will not be evaluated in
this study since published evidence on its acceptability
and success rate at the intended primary site already ex-
ists [13].
Population/sample
Participants will be pregnant women aiming for a vagi-
nal birth who plan to give birth at North Bristol NHS
Trust (NBT), Bristol, UK. Recruitment is projected to
continue for 8 months (due to the AVB rate within the
Fig. 3 CONSORT diagram of the ASSIST feasibility study. AVB assisted vaginal birth, NIP Neonatal Infant Pain
Fig. 2 The BD Odon Device component parts
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department) after which time it is estimated that 40 sets
of primary outcome data will have been recorded.
Prospective participants will receive information on
the study in early pregnancy (12 to 28 weeks) via the
NBT Maternity ‘App’ (this ‘App’ is provided to all preg-
nant women at NBT and provides information on all
aspects of their maternity care) and paper information
leaflets given to women at any hospital admission. Mem-
bers of the study team will then approach women after
28 completed weeks of pregnancy during antenatal
appointments or antenatal admissions to discuss the
study and offer women the opportunity to watch a video
explaining the study. Women who are willing to take
part (should they require an AVB) will then be invited to
provide informed written consent. Figure 4 demonstrates
the schedule of enrolment, interventions, and assessments.
When a woman who has previously consented to par-
ticipate in the study arrives on the labour ward, her eligi-
bility to participate in the study will be re-checked by a
midwife and obstetrician that have been trained in Good
Clinical Practice (GCP), and verbal re-confirmation of
her consent to take part in the study will be sought by a
GCP-trained midwife or obstetrician. Case report forms
can be found in Additional file 1.
Inclusion and exclusion criteria
Women will be able to participate in the ASSIST Study
if all of the following apply at initial consent: the woman
is ≥18 years of age; the woman has a singleton pregnancy
of at least 36 weeks gestation; there is a negative ante-
natal screen for HIV and hepatitis B; the woman is in
labour and requires an assisted vaginal birth for a clin-
ical indication (as per the Royal College of Obstetrics
and Gynaecology (RCOG) Greentop Guideline 26 [8]);
the RCOG specific requirements for AVB are fulfilled;
the woman has effective analgesia in place during the
use of the instrument (i.e. epidural, spinal or pudendal
block, or perineal infiltration with local anaesthetic); and
there is no obstetric indication for an alternative method
of AVB.
Women will not be able to take part in the ASSIST
Study if: there is a diagnosis of a fetal skull abnormality
precluding AVB (i.e. macrocephaly); there is a known
osteogenesis imperfecta affected pregnancy; there is
suspicion of a fetal bleeding disorder (von Willebrand’s
disease, autoimmune thrombocytopenia (AITP), haemo-
philia); there is an intrauterine fetal death in the current
pregnancy; the woman is sensitive to latex; the woman is
currently serving a prison sentence; or the indication for
Fig. 4 Schedule of enrolment, interventions, and assessments. AVB assisted vaginal birth, PN post-natal
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AVB is a fetal bradycardia which is present, ongoing,
and has not recovered.
Intervention
If the obstetrician attending an eligible woman during
the second stage of labour, and who has previously pro-
vided informed written consent to take part in the study,
determines that an AVB is indicated, they will explain
this to the woman as per standard practice. If the
woman agrees to an AVB, an accoucheur who has had
specific training in using the BD Odon Device
(Additional file 2) will assist the birth with the BD Odon
Device. Should the birth not be achieved with the BD
Odon Device, the accoucheur will use their clinical
judgement on an individual case basis to complete the
birth using ventouse, forceps, or caesarean section as ap-
propriate. Primary, secondary, safety, and qualitative re-
search data will be gathered regarding the assisted birth
and use of the device.
Clinical, safety, and process outcomes
Primary outcome
The primary outcome will be the proportion of births
successfully assisted with the BD Odon Device. A birth
will be defined as ‘successful’ if all of the six criteria in
Table 1 are met.
Safety outcomes
The maternal safety outcomes are:
 Weighed/measured blood loss in the first 6 h
following birth (post-partum haemorrhage ≥3000
ml);
 Third- or fourth-degree tear;
 Cervical tear requiring suturing;
 Requirement for general anaesthesia;
 Shoulder dystocia;
 Use of emergency caesarean section to achieve birth;
 Maternal death.
The neonatal safety outcomes are:
 Apgar score <7 at 5 min;
 Pressure necrosis of fat or skin;
 Neonatal soft tissue trauma (bruise/scalp/facial
injury);
 Neonatal vascular injury (haemorrhage/
cephalohaematoma/subaponeurotic haemorrhage);
 Neonatal skeletal injury (bone fracture);
 Neonatal intracranial injury (cerebral contusion);
 Neonatal neurological injury still present at 28 days
after birth;
 Neonatal seizure;
 Phototherapy for jaundice contributed to by
bruising;
 Death within 28 days after birth.
The device safety outcomes are:
 Failure of a component of the BD Odon Device;
 Number of applications of device;
 Number of pulls with the BD Odon Device.
Secondary outcomes
The clinical secondary outcomes are:
 Failure to achieve a vaginal birth with the assistance
of the BD Odon Device and mode of birth
thereafter;
 Method of infant feeding (day 1, 7, 28, and 90 post-
natal);
 Time from ‘decision to perform assisted birth’ to
‘birth’ (minutes);
 Time from ‘device application’ to ‘birth’ (minutes);
 Time to achieve regular respirations (minutes);
 Episiotomy and perineal trauma;
 Umbilical arterial and venous pH and base excess;
 Other neonatal injury;
 Neonatal pain (Neonatal Infant Pain Score (NIPS) at
2 and 6 h after birth);
Table 1 Primary outcome
Criterion Source Collected by
The birth of the baby is expedited with the BD Odon Device AVB pro-forma medical
notes
Research team member including device
operator




Research team member including device
operator




Research team member including device
operator
There are no serious adverse device effects AVB pro-forma medical
notes
Research team member including device
operator
The woman’s perception of her birth is rated above a score of 6 Case report form Research team member
The practitioner reported outcome is above 12. Case report form Device operator
AVB assisted vaginal birth
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 Time spent in neonatal intensive care unit (hours);
 Anaemia requiring transfusion;
 Neonatal encephalopathy requiring therapeutic
hypothermia within 28 days after birth;
 Organ failure within 28 days after birth;
 Failure to establish a normal feeding pattern, defined
as ≤1 feed at 10 h of age.
The women-reported secondary outcomes are:
 Maternal health-related quality of life data (by EQ-
5D-5 L antenatally at the time of consent, at day 1,
and day 28 post-natal);
 Maternal satisfaction with birth experiences (Patient
Perception Score on day 1 post-natal);
 Maternal perception of pain (day 1, 7, and 28 post-
natal);
 Health service utilisation will be collected (day 28
post-natal);
 Maternal continence at 90 days.
The practitioner-reported secondary outcomes are:
 Willingness to use the BD Odon Device;
 Perceived overall ease of use of device;
 Ease of device set-up;
 Ease of device application to the baby’s head;
 Ease of withdrawal of the applicator after
application;
 Comfort with the level of force required to assist the
birth of the baby;
 Ease of deflation of the air chamber prior to
crowning.
Safety of the intervention
A comprehensive assessment of the safety of the BD
Odon Device will be undertaken following every
attempted birth within the ASSIST Study. Outcome
measures and data collected will ensure capture of any
potential adverse events associated with the BD Odon
Device at the time of birth by the operator and/or a
member of the research team (see Additional file 1 for
details of case report forms). Follow-up will be per-
formed by the research team. In the immediate post-par-
tum period, a member of the research team will
follow-up the participant on a daily basis until discharge,
collecting the day 1 data. To ensure that any serious
adverse events that occur in the post-natal period are
captured, an Adverse Event Reporting System will be ini-
tiated on the post-natal wards for ward staff to highlight
any serious adverse events that occur after discharge
from the labour ward. Post-natal staff will be asked to
notify a member of the research team if any such events
occur. In addition, device failure (or failure of any
component) will be reported as an individual outcome
measure. Follow-ups at day 7, 28, and 90 will be con-
ducted by a member of the research team by telephon-
ing the woman using their contact details provided to
the study team. The Trial Management Group (TMG)
and Sponsor will regularly review data from all births ac-
cording to the schedule in Additional file 3 to ensure
early identification of any trends of adverse events. All
adverse events will be classified and reported according
to the schedule of the Medicines and Healthcare Regula-
tion Agency (MHRA) and the Research Ethics
Committee.
Recruitment and process outcomes
To facilitate the development of the main trial, informa-
tion will be collected on the number of women screened,
those identified as eligible and approached, and those
who consented to participate both in advance of labour
and again during labour where applicable. Information
on data completion, i.e. questionnaire completion, com-
pletion of main outcomes, and missing data, will also be
reported. Reasons for ineligibility, participation refusal,
loss to follow-up, or missing data will also be explored.
Patient and public involvement
Women and their partners have been involved through-
out the development of the ASSIST Study. Formal pa-
tient and public involvement (PPI) panels have reviewed
the proposed study design, patient-facing documentation
(leaflets, videos, and consent forms), and have supported
both the general and specific aims of the study. The
Trial Steering Committee (TSC) of the ASSIST Study in-
cludes a lay patient representative.
Sample size and analysis
A complete sample size of 40 women will enable the es-
timation of the rate of successful assisted vaginal birth of
80% to within a 95% confidence interval of ±12%. The
sample size will also demonstrate AVB requiring use of a
secondary instrument of 50% to within a 95% confidence
interval of ±15%.
Quantitative description
The primary, secondary, and safety data will be reported
as the frequency and proportion, mean (and standard
deviation), or median (and interquartile range) depend-
ing on their nature and distribution. The overall rate of
successful AVB birth will be reported and the frequency
of unsuccessful births will be reported by the six criteria
defined for success. Appropriate outcomes will be pre-
sented and broken down into subgroups by operator ex-
perience (>10 years or <10 years), indication for assisted
vaginal birth (fetal compromise or other indication of
AVB), participant analgesia (regional anaesthetic or other
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analgesia), fetal station (0 and +1 cm to spines or +2 and
+3 cm to spines), and fetal position (OA or OT or OP).
The overall number of safety events will be reported, as
well as the number of events by the main reason for
adverse events. Events related to device failure and/or
mis-use of the device will also be described.
The recruitment and process outcomes will be re-
ported as frequencies and percentages. Completion rates
of the clinical outcomes will also be reported. Reasons
for ineligibility, refusal, loss to follow-up, or missing data
will be categorised and described as frequencies.
Data on numbers screened, those identified as eligible
and approached, those consenting to participate both in
advance of labour and again during labour where applic-
able, those included in follow-up and those providing
questionnaire and outcome data and successful birth
rates will all inform the sample size calculation of the
main trial. During the trial, there will be a continuous
review of mother and baby safety from the Sponsor and
TMG, and a decision will be made as to whether to con-
tinue, revise, or stop the trial.
Women and their babies will be followed up at 1 day, 7
days, 28 days, and 90 days following the birth. A woman
and her baby will be deemed to complete their participa-
tion in the study at 90 days after the birth.
Integrated qualitative research
Alongside the primary clinical study, an integrated quali-
tative study (IQS) within the feasibility study will be
undertaken. This will investigate: the practitioners’ use
of the device to ensure that an appropriate training
package is developed for the trial; enable the interven-
tion to be described and refined to optimise its use; and
to investigate the woman’s, obstetrician’s, midwife’s, and
neonatologist’s perspective of the birth and what they
consider to be characteristics of a ‘good birth’. This will
enable the research team to incorporate these findings
into any subsequent RCT, as well as iteratively altering
the ASSIST Study plan if required.
The qualitative study will combine observational and
interview data collection and analysis. AVBs involving
successful or attempted use of the BD Odon device will
be observed wherever possible. Successful or attempted
births will be followed up with interviews with obstetri-
cians, midwives, and women to triangulate their experi-
ences and views with what has been observed.
Trial oversight
A TMG consisting of all investigators and co-investigators
will be responsible for the day-to-day running of the study.
The study will be overseen by two committees, the
Independent Data Monitoring Committee (IDMC) and
the Trial Steering Committee (TSC). The IDMC will sit
after 20 and 40 births have been completed and will have
no direct involvement in the running of the trial. Follow-
ing both reviews, the IDMC will generate a report on
the performance of the device and the safety of partici-
pants. These reports will be reviewed by the TSC and
the Sponsor. The TSC will consist of an independent
clinical expert, statistician, and a lay representative, to-
gether with the investigators and representative. The
TSC will review all reports produced by the IDMC and
make a recommendation to the Sponsor following every
review to continue, modify, or halt the study. The TSC
will provide oversight of the progress of the study and
ensure the study is conducted according to the princi-
ples of GCP. Auditing will take place when requested by
the Sponsor.
Dissemination
Study results will be published within 1 year of comple-
tion of data collection in an appropriate peer-reviewed,
open-access journal. The results will be presented at
local, national, and international meetings. Summaries
will also be distributed using existing parent networks. A
summary of results will also be sent to all women who
participated in the study, unless they express their wish
not to receive such information. Results will be commu-
nicated to a lay audience by social media activities of
North Bristol NHS Trust, the University of Bristol, and
the research team.
Discussion
An appropriately conducted AVB, performed when clin-
ically indicated, is associated with improved maternal
and neonatal outcomes when compared with caesarean
section in the second stage of labour or compared with
no action [3]. AVB is currently not performed in many
low- and middle-income settings where it may be of
significant benefit to individual woman and their babies
in reducing birth-related morbidity and mortality [14].
Current efforts to promote the use of AVB in these set-
tings have been insufficiently effective which may be due
to the inherent limitations of the existing instruments.
Therefore, the development of a new device for AVB is
both justified and required [15].
The BD Odon Device is the first new device for AVB
since the introduction of ventouse into clinical practice in
the 1950s [16]. Extensive pre-clinical simulation testing
has suggested that it is not likely to generate additional
pressure over the fetal head compared with current instru-
ments [9, 17], is not likely to generate clinically significant
levels of neonatal hypoxia if misplaced over the fetal
carotid arteries [10], and is not likely to be associated with
unsafe patterns of use by the target user population [12].
We believe that it is therefore reasonable to proceed to a
clinical feasibility study of the device, and, if positive, a
randomised controlled trial.
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If found safe by the TSC, IDMC, and Sponsor, findings
from this feasibility study will inform the design of a
randomised controlled trial that may produce evidence
that supports the introduction into clinical practice of a
new device for AVB. If this were able to address the un-
met need for AVB around the world it would have a
major impact on the management of complications in
the second stage of labour and maternal and neonatal
outcomes worldwide.
Trial status
The ASSIST Study is scheduled to commence on 8 Oc-
tober 2018, using version 16.10. The study will cease
after 40 complete sets of primary outcome data are re-
ceived. This is projected to be in May 2019.
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